OBJECTIVE: To determine the rate of progression of mild cognitive impairment (MCI) to dementia with Lewy bodies (DLB). METHODS: We followed 337 patients with MCI in the Mayo Alzheimer's Disease Research Center (range 2-12 years). Competing risks survival models were used to examine the rates of progression to clinically probable DLB and Alzheimer disease (AD). A subset of patients underwent neuropathologic examination. RESULTS: In this clinical cohort, 116 remained as MCI, while 49 progressed to probable DLB, 162 progressed to clinically probable AD, and 10 progressed to other dementias. Among nonamnestic MCI, progression rate to probable DLB was 20 events per 100 person-years and to probable AD was 1.6 per 100 person-years. Among amnestic MCI, progression rate to probable AD was 17 events per 100 person-years, and to DLB was 1.5 events per 100 person-years. In 88% of those who developed probable DLB, the baseline MCI diagnosis included attention and/or visuospatial deficits. Those who developed probable DLB were more likely to have baseline daytime sleepiness and subtle parkinsonism. In 99% of the clinically probable AD group, the baseline MCI diagnosis included memory impairment. Neuropathologic confirmation was obtained in 24 of 30 of those with clinically probable AD, and in 14 of 18 of those with clinically probable DLB. CONCLUSION: In a clinical sample, patients with nonamnestic MCI were more likely to develop DLB, and those with amnestic MCI were more likely to develop probable AD.
OBJECTIVE: To determine the rate of progression of mild cognitive impairment (MCI) to dementia with Lewy bodies (DLB). METHODS: We followed 337 patients with MCI in the MayoAlzheimer's Disease Research Center (range 2-12 years). Competing risks survival models were used to examine the rates of progression to clinically probable DLB and Alzheimer disease (AD). A subset of patients underwent neuropathologic examination. RESULTS: In this clinical cohort, 116 remained as MCI, while 49 progressed to probable DLB, 162 progressed to clinically probable AD, and 10 progressed to other dementias. Among nonamnestic MCI, progression rate to probable DLB was 20 events per 100 person-years and to probable AD was 1.6 per 100 person-years. Among amnestic MCI, progression rate to probable AD was 17 events per 100 person-years, and to DLB was 1.5 events per 100 person-years. In 88% of those who developed probable DLB, the baseline MCI diagnosis included attention and/or visuospatial deficits. Those who developed probable DLB were more likely to have baseline daytime sleepiness and subtle parkinsonism. In 99% of the clinically probable AD group, the baseline MCI diagnosis included memory impairment. Neuropathologic confirmation was obtained in 24 of 30 of those with clinically probable AD, and in 14 of 18 of those with clinically probable DLB. CONCLUSION: In a clinical sample, patients with nonamnestic MCI were more likely to develop DLB, and those with amnestic MCI were more likely to develop probable AD.
Authors: P Fischer; S Jungwirth; S Zehetmayer; S Weissgram; S Hoenigschnabl; E Gelpi; W Krampla; K H Tragl Journal: Neurology Date: 2007-01-23 Impact factor: 9.910
Authors: Ronald C Petersen; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; Glenn E Smith; Clifford R Jack Journal: Arch Neurol Date: 2009-12
Authors: M M Machulda; R J Ivnik; G E Smith; T J Ferman; B F Boeve; D Knopman; R C Petersen; E G Tangalos Journal: J Clin Exp Neuropsychol Date: 2007-05 Impact factor: 2.475
Authors: R B Postuma; J F Gagnon; M Vendette; M L Fantini; J Massicotte-Marquez; J Montplaisir Journal: Neurology Date: 2008-12-24 Impact factor: 9.910
Authors: Mark W Bondi; Emily C Edmonds; Amy J Jak; Lindsay R Clark; Lisa Delano-Wood; Carrie R McDonald; Daniel A Nation; David J Libon; Rhoda Au; Douglas Galasko; David P Salmon Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: R Scott Mackin; Philip Insel; Jing Zhang; Brian Mohlenhoff; Douglas Galasko; Michael Weiner; Niklas Mattsson Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: David P Sheppard; Jennifer E Iudicello; Mark W Bondi; Katie L Doyle; Erin E Morgan; Paul J Massman; Paul E Gilbert; Steven Paul Woods Journal: J Neurovirol Date: 2015-07-03 Impact factor: 2.643
Authors: Jeffrey N Motter; Gregory H Pelton; Kristina D'Antonio; Sara N Rushia; Monique A Pimontel; Jeffrey R Petrella; Ernst Garcon; Michaela W Ciovacco; Joel R Sneed; P Murali Doraiswamy; Davangere P Devanand Journal: Int J Geriatr Psychiatry Date: 2018-07-23 Impact factor: 3.485
Authors: Bing Zhang; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Mandie Maroney-Smith; Anthony J Spychalla; David S Knopman; Clifford R Jack; Ronald C Petersen; Kejal Kantarci Journal: J Neuroimaging Date: 2014-07-15 Impact factor: 2.486
Authors: Christine M Belden; Vickram Kahlon; Michael Malek-Ahmadi; Andrew Tsai; Marwan N Sabbagh Journal: Am J Alzheimers Dis Other Demen Date: 2014-07-09 Impact factor: 2.035